News

Article

Cytiva Invests $500 Million Over 5 years to Expand Global Capacity

The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.

On Sept. 13, 2020, Cytiva, announced that it is investing $500 million over five years to expand its global manufacturing capacity. The company will also hire nearly 1000 personnel in key areas as part of its strategy to support long-term growth in the biotechnology industry.

The investment will include new manufacturing lines that incorporate single-use technologies, equipment, and infrastructure at multiple sites, as Cytiva's capacity to manufacture single-use products will more than double, according to a company press release. In Asia-Pacific, single-use capacity will triple through a partnership with Wego, a large healthcare technology supplier in China that is already producing consumables for Cytiva in the region.

Cell culture media production will increase as the result of new manufacturing lines, cleanroom space, personnel, and additional personnel shifts at the company’s site in Logan, UT. Further, the company’s locations in Singapore and Pasching, Austria, are increasing output through increased personnel and additional work shifts, following a tenfold increase in powdered cell culture media production announced in May 2018.

The manufacturing capacity of Cytiva's MabSelect and Capto chromatography product platforms has also doubled as part of a $70-million-per-year (2017–2022) investment in capacity gains and a facility modernization program at its Uppsala, Sweden, site. The Uppsala plant is now fully automated with the latest technology to allow for continuous manufacturing. Other elements of the Uppsala investment include a capacity extension of Sephadex resin, which sets up additional facilities for in-house manufacturing, and the development of automation and digitalization infrastructure.

Cytiva is also investing in a new facility in Grens, Switzerland, to manufacture single-use kits for its Sepax and Sefia cell processing systems for the cell and gene therapy market.

"We know from our customers that availability and lead time are the most important considerations after quality. Cytiva's long-term commitment is to deliver the best product, at the right time, and support our customers with expertise. The industry is growing rapidly, now even more due to COVID-19. Accelerating this investment will reinforce these commitments,” said Emmanuel Ligner, president and CEO, Cytiva, in the press release. "Dual manufacturing assures our customers that if one location encounters capacity constraints, we have plenty of back-up ready to activate."

Source: Cytiva

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content